Article Text

Download PDFPDF
Long-term tumour dormancy in a BRCA1 heterozygote

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @Setfelix

  • Contributors SA performed data analysis and visualisation, and contributed to the manuscript draft; LF reviewed pathology and contributed to the draft; ND wrote the first draft; BR oversaw some of the experiments; CD carried out some of the Sanger sequencing; LdK prepared the samples and did some of the Sanger sequencing; NH oversaw some of the experiments; LG provided clinical data; PP oversaw data analysis; JR oversaw the whole-exome sequencing; WDF devised the project, oversaw the work and finalised the manuscript draft. All authors approved the submitted manuscript.

  • Funding The work in WDF’s lab was funded by a Canadian Institutes of Health Research Foundation Grant (FDN-148390).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.